Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-954561
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BMS-954561 is an investigational small molecule drug developed by Bristol Myers Squibb for the treatment of neuropathic pain conditions, specifically postherpetic neuralgia and diabetic peripheral neuropathic pain. It acts as a modulator of both GABA receptors and nicotinic acetylcholine receptors (nAChRs), targeting key pathways involved in neuronal excitability and pain signaling. The drug was classified as a novel analgesic with dual GABA/nicotinic modulatory activity. Clinical development reached phase 2 trials for both indications but has since been discontinued[1][2][9].
- Other names
- GABA/nicotinic modulator (neuroscience), BMS
02
Targets
Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on BMS-954561.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-954561.